CHA Vaccine Institute (KOSDAQ: 261780) – Pioneering Next-Generation Vaccines & Immunotherapies CHA Vaccine Institute is a cutting-edge biotechnology company dedicated to developing transformative therapeutic and prophylactic vaccines, as well as innovative cancer immunotherapies. Proprietary Adjuvant Platforms: Our TLR2/TLR3 agonist combination significantly enhances vaccine efficacy and anti-cancer immune responses. Addressing Critical Medical Needs: Targeting high-value markets, including Chronic Hepatitis B ($5.6B) and Herpes Zoster ($5.0B). Robust Clinical Pipeline: Advancing three clinical trials, including a Phase 2b vaccine and two Phase 1 prophylactic vaccines. Strong Intellectual Property Portfolio: Protecting innovation with 40 global patents. Expert Leadership: Led by a team of seasoned biotech professionals driving innovation and growth.
Certest Biotec
Certest Biotec, established in Spain in 2002 as an innovative and technology-based company, has always based its growth on the research and development of new products, and the exploration for new market niches and opportunities. The key to understand its success is the way to understand its organization: highly specialized and customer oriented. Certest Pharma part of Certest Biotec, is dedicated to building a platform for the development of RNA vaccines and oligotherapeutics, with a special focus on seeking improved formulations to enhance delivery. In that sense, Certest Pharma is specialized in the development of raw materials, amongst which lipids and more specifically, ionizable lipids, are one of the leading products. Certest´s Pharma three main areas are: Delivery technology: Ionizable lipids are a key element in the production of lipid nanoparticles (LNPs), and as such, have been widely used for the systemic delivery of RNA therapeutics. After the screening of more than a thousand ionizable lipids with our semi-rational design we are able to offer outperforming and custom made ionizable lipids for the effective targeted delivery of RNA therapeutics. API platform: This platform will cover, thanks to over 20 years of experience in the field, all the necessary steps for the design, development, and evaluation of effective mRNA and oligotherapeutics molecules. Also, a proprietary UTR sequence and codon optimization software have been developed showing higher results in protein expression. Enzymes for the production of mRNA have also been developed. Therapeutic products: Bringing together both areas Certest was granted to develop a new booster for TB vaccine and therefore be able to show the full capabilities of the company.
Centre for Translational Stem Cell Biology
Centre for Translational Stem Cell Biology (CTSCB) provides Hong Kong with an opportunity to excel in scientific and medical research. A team of top-notch scientists and clinicians from the University of Hong Kong and the University of Cambridge collaborates to elevate stem cell technology to new heights. By leveraging a pioneering patented technology, Expanded Potential Stem Cells (EPSCs), CTSCB is dedicated to advancing fundamental research and translating discoveries into regenerative medicine, organ transplantation and genomic medicine for the benefit of people worldwide. CTSCB primarily focuses on producing mature and functional cells for regenerative medicine with the patented technology, enabling in-depth study of immune disease mechanism, and expediting the development of antiviral, anti-ageing natural products and antibody drugs. Our vision is to translate medical discoveries and homegrown technologies into applications that not only serve medical and biotechnological purposes but also extend to the agricultural sector, fostering the growth of innovation and technology. | Imagine a future where healthcare is transformed by cutting-edge stem cell technology. Centre for Translational Stem Cell Biology (CTSCB), a collaboration between the University of Hong Kong and the University of Cambridge, supported by the Innovation and Technology Commission, is at the forefront of making this vision a reality. Leveraging patented Expanded Potential Stem Cell (EPSC) technology, we can create any cell type, both embryonic and extra-embryonic, offering immense potential for regenerative medicine and therapeutic applications. Our research focuses on intelligent drug screening, precision medicine and cell-based therapies. We develop next-generation stem cell technology that improves patient outcomes and enhances quality of life. Our drug screening platforms support pharmaceutical and health supplement companies in streamlining their development processes using multicellular organoid systems and personalized disease modelling. We also explore health and cosmetic products derived from EPSC technology, with interests in product co-development to address various health issues. By attracting top global talent and fostering innovation, CTSCB is well-positioned to enhance therapeutic applications and promote longevity. Through our innovative research and commitment to excellence, CTSCB aims to lead the way in revolutionary healthcare solutions for generations to come.
cellNUA KSA
cellNUA is a biotechnology company transforming how the world approaches infectious disease, immune dysfunction, and cellular regeneration—by unlocking the therapeutic intelligence of nature itself. Founded in Galway, Ireland, with a growing international presence, cellNUA merges evolutionary biology, nanomedicine, and advanced bioinformatics to create naturally inspired, scientifically validated interventions. At its core is a belief that the cell is not a passive victim of disease, but an active architect of its own defense. Our goal is to decode the biochemical logic that governs this cellular resilience and translate it into scalable healthcare platforms. Our flagship platform, BEEMAR™, is the first immune system technology built on comparative glyco-genomics between honeybees and humans. It harnesses the honeybee’s highly evolved immune response—one that is faster than human immunity and uniquely precise—alongside regenerative compounds from marine ecosystems. Through proprietary inoculation and extraction protocols, BEEMAR™ produces pathogen-specific biologics that target viruses, bacteria, and parasites without relying on traditional synthetic drugs. Preclinical trials have shown remarkable reductions in viral load—including against COVID-19, polio, and herpes—and significant inhibition of the malaria parasite, all with no observed cytotoxicity. Supporting platforms like CellMar78™ and Occunase™ extend our approach from therapeutic to preventative medicine. CellMar78™ is a marine-derived, isotonic delivery medium designed for safe gene therapy, stem cell support, and regenerative research. Occunase™, a drug-free nasal spray, forms a mechanical barrier in the nasal mucosa to block respiratory pathogens and allergens—a practical, immune-independent defense for public health. cellNUA’s research is rooted in deep omics analysis, high-throughput screening, and a platform-based architecture that allows rapid adaptation to emerging threats. Our partnerships with institutions such as Johns Hopkins University and Trinity College Dublin, as well as preclinical validations in Europe and Africa, reinforce our commitment to rigorous science and global health equity. With a vision to localize biotech solutions through decentralized “BioCities,” beginning in Europe and the Middle East, we aim to reduce global dependence on imported therapeutics and empower regions with rapid-response health infrastructure. Our work is not only about treatments—it is about restoring trust in biology’s original intelligence and equipping humanity with systems that are proactive, precise, and profoundly sustainable. cellNUA: Where Nature’s Intelligence Becomes the Blueprint for Modern Medicine.
Ceidos
Bioproduction is complex particularly during cell expansion in bioreactors. Current methods to assess the viability, density and shape of mammalian cells are highly manual and require recurrent sampling. The C-Netics enables non-destructive and label-free analysis in real time. It works coupled to a dedicated single use kit that integrates an analysis cassette with high-end microelectronic sensors. The monitoring can then be run automatically during the entire duration of the cell culture.This allows the detection of anomalies in real-time and can also be used to quickly optimize a process development. | Ceidos offers an automatic laboratory device that improves the biopharmaceutical production process. Faced with the challenge of slow, manual control of cell cultures, Ceidos introduces the C-Netics, a sophisticated device compatible with most bioreactors. It enables automated, real-time cell culture analysis with a single-use kit, increasing efficiency, reducing contamination and guaranteeing high-quality results, revolutionizing laboratory work and setting new standards in the field of biotechnology. Ceidos SA is a pioneering biotechnology company based in Monthey, Switzerland and founded in 2019. Specializing in the development of innovative solutions for the biopharmaceutical industry, Ceidos is expert in advanced technologies such as microscopy, microelectronics, and machine learning allowing the development of breakthrough bioprocessing devices. | Ceidos aims to revolutionize biopharmaceutical production with C-Netics, an advanced system for real-time, non-destructive cell culture monitoring. By integrating microscopy, dielectrophoresis, and AI-driven analysis, C-Netics ensures precise control of cell viability, density, and culture conditions. Unlike traditional methods, it connects directly to bioreactors, minimizing contamination risks and reducing manual interventions. Ceidos collaborates with industry leaders and CMOs/CDMOs to optimize bioprocesses, enhance efficiency, and improve the scalability of advanced therapies like CAR-T and monoclonal antibodies.
Calviri, Inc.
Calviri is early phase company focused on diagnostics to detect cancer early and vaccines to treat or even prevent cancer. We are completing a 5-year, 800 dog clinical trial that demonstrates efficacy and safety of our broadly preventative cancer vaccine. We will initiate sales of the vaccine in 2025 and initiate human trials. Our diagnostic is able to detect stage 1 tumors with high sensitivity using a completely new platform. We will initiate sales of the dog diagnostic in 2024. Calviri is poised to transform cancer for both dogs and people. | Calviri’s mission is to End Cancer – Worldwide. We have made the discoveries and invented the technologies that make this mission possible. We will deliver products for stage 1 cancer detection, a vaccine to treat, and ultimately a vaccine to prevent canine cancer.
Brazilian Center for Research – CNPEM
CNPEM is a sophisticated and ebullient environment for research and development that is the only one of its kind in Brazil and found in only a few scientific centers in the world. The Center private, non-profit organization overseen by the Ministry of Science, Technology, and Innovation (MCTI). The Center is home to Sirius, the most complex project in Brazilian science and one of the world’s most advanced synchrotron light sources. CNPEM comprises highly specialized multi-thematic teams, globally competitive lab infrastructure that is open to the scientific community, strategic lines of research, innovative projects in partnerships with the productive sector, and training programs for researchers and students. CNPEM is an environment driven by research into solutions that impact the areas of health, energy and renewable materials, agro environmental and engineering. | The Brazilian Center for Research in Energy and Materials (CNPEM) is home to a state-of-the-art, multi-user and multidisciplinary scientific environment. A social organization overseen by the Ministry of Science, Technology and Innovation, CNPEM powers Brazil’s science with cutting-edge labs like Sirius, tackling global challenges in health, renewable materials, energy & sustainability.
BIORON GmbH
BIORON GmbH is a trusted manufacturer and global distributor of molecular biology tools and diagnostic solutions with over 20 years of experience. Located in Germany, we specialize in raw materials for PCR applications and human DNA products (like Human Placenta DNA or COT I Human DNA) e. g. for hybridization assays. Certified according to ISO 13485 standards, we ensure that our products meet highest quality and health requirements. Our dedicated Team includes highly motivated and qualified scientists and molecular biology experts. BIORON is committed to provide advanced solutions for life science research and diagnostic production.
Biopôle SA
Biopôle Lausanne is one of the largest life sciences campus in Europe, hosting a vibrant community of world-renowned industry players and research institutes, based in Lausanne, Switzerland (www.biopole.ch). It offers a world-class combination of modern infrastructure (134,000 sqm of office/lab space), added value services, an extensive network, innovation and funding programmes, and unparalleled community engagement where members can thrive and bring science to life. Biopôle houses 130+ life sciences companies, including 50 biotech/pharma such as Ferring, Roche, Ichnos, etc. and world-class research organizations (Lausanne University Hospital (CHUV), University of Lausanne (UNIL), the Ludwig Institute for Cancer Research etc.), a life science incubator (StartLab), ready-to-move-in private labs (Superlab), a Digital Health Hub (DH2) enabling the emergence of outstanding innovation for the betterment of healthcare. Join Biopôle.